<SEC-DOCUMENT>0001019056-16-001183.txt : 20160315
<SEC-HEADER>0001019056-16-001183.hdr.sgml : 20160315
<ACCEPTANCE-DATETIME>20160315140708
ACCESSION NUMBER:		0001019056-16-001183
CONFORMED SUBMISSION TYPE:	NSAR-B/A
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131231
FILED AS OF DATE:		20160315
DATE AS OF CHANGE:		20160315
EFFECTIVENESS DATE:		20160315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DAXOR CORP
		CENTRAL INDEX KEY:			0000027367
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				132682108
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		NSAR-B/A
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-22684
		FILM NUMBER:		161506425

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7120
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		2122440555

	MAIL ADDRESS:	
		STREET 1:		350 5TH AVENUE
		STREET 2:		SUITE 7120
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDANT CORP
		DATE OF NAME CHANGE:	19730823
</SEC-HEADER>
<DOCUMENT>
<TYPE>NSAR-B/A
<SEQUENCE>1
<FILENAME>daxor_nsarba.fil
<DESCRIPTION>NSAR-B/A
<TEXT>
<PAGE>      PAGE  1
000 B000000 12/31/2013
000 C000000 0000027367
000 D000000 N
000 E000000 NF
000 F000000 Y
000 G000000 Y
000 H000000 N
000 I000000 6.1
000 J000000 A
001 A000000 Daxor Corporatiaon
001 B000000 811-22684
001 C000000 2123308500
002 A000000 350 Fifth Avenue, Ste 7120
002 B000000 New York
002 C000000 NY
002 D010000 10118
003  000000 Y
004  000000 N
005  000000 N
006  000000 N
007 A000000 N
007 B000000  0
013 A000001 Rotenberg Meril Solomon Bertiger Guttilla PC
013 B010001 Saddle Brook
013 B020001 NJ
013 B030001 07663
018  000000 N
019 A000000 N
020 A000001 UBS Financial Services
020 B000001 13-2638166
020 C000001     94
020 A000002 TD Ameritrade
020 B000002 47-0533629
020 C000002     22
021  000000      116
022 A000001 UBS Financial Services
022 B000001 13-2638166
022 C000001      2071
022 D000001      7954
022 A000002 TD Ameritrade
022 B000002 47-0533629
022 C000002       658
022 D000002      3533
022 A000003 Brill Securities
022 B000003 13-3363538
022 C000003         8
022 D000003         0
023 C000000       2737
023 D000000      11487
024  000000 N
026 A000000 N
<PAGE>      PAGE  2
026 B000000 N
026 C000000 N
026 D000000 Y
026 E000000 N
026 F000000 N
026 G010000 N
026 G020000 N
026 H000000 N
027  000000 N
045  000000 N
055 A000000 N
055 B000000 N
056  000000 N
057  000000 N
058 A000000 N
059  000000 Y
060 A000000 N
060 B000000 N
061  000000        0
062 A000000 N
066 A000000 N
067  000000 N
068 A000000 N
068 B000000 N
069  000000 N
070 A010000 Y
070 A020000 N
070 B010000 Y
070 B020000 Y
070 C010000 Y
070 C020000 N
070 D010000 Y
070 D020000 N
070 E010000 Y
070 E020000 N
070 F010000 Y
070 F020000 N
070 G010000 Y
070 G020000 N
070 H010000 Y
070 H020000 N
070 I010000 Y
070 I020000 N
070 J010000 Y
070 J020000 N
070 K010000 Y
070 K020000 N
070 L010000 N
070 L020000 N
070 M010000 N
070 M020000 N
<PAGE>      PAGE  3
070 N010000 Y
070 N020000 N
070 O010000 Y
070 O020000 N
070 P010000 N
070 P020000 N
070 Q010000 Y
070 Q020000 Y
070 R010000 Y
070 R020000 Y
071 A000000      2737
071 B000000     11487
071 C000000     46693
071 D000000    6
072 A000000 12
072 B000000        0
072 C000000     2048
072 D000000        0
072 E000000        0
072 F000000        0
072 G000000        0
072 H000000        0
072 I000000       57
072 J000000        0
072 K000000        0
072 L000000        0
072 M000000        0
072 N000000        0
072 O000000    -3762
072 P000000      205
072 Q000000        0
072 R000000      112
072 S000000       17
072 T000000        0
072 U000000        0
072 V000000        0
072 W000000      237
072 X000000    -3134
072 Y000000        0
072 Z000000     5182
072AA000000     6068
072BB000000    13202
072CC010000        0
072CC020000     6266
072DD010000        0
072DD020000        0
072EE000000        0
073 A010000    .0000
073 A020000    .0000
073 B000000    .0000
073 C000000    .0500
<PAGE>      PAGE  4
074 A000000        0
074 B000000        0
074 C000000        0
074 D000000        0
074 E000000     1627
074 F000000    41019
074 G000000        0
074 H000000        0
074 I000000        3
074 J000000        0
074 K000000        0
074 L000000     1389
074 M000000     3356
074 N000000    47394
074 O000000    20245
074 P000000        0
074 Q000000        0
074 R010000        0
074 R020000        0
074 R030000      715
074 R040000       63
074 S000000        0
074 T000000    26371
074 U010000     4090
074 U020000        0
074 V010000     6.45
074 V020000      .00
074 W000000    .0000
074 X000000      675
074 Y000000        0
075 B000000      000
076  000000    00.00
077 A000000 Y
077 B000000 N
077 C000000 N
077 D000000 N
077 E000000 N
077 F000000 N
077 G000000 N
077 H000000 N
077 I000000 N
077 J000000 N
077 K000000 N
077 L000000 N
077 M000000 N
077 N000000 N
077 O000000 N
077 P000000 N
077 Q010000 N
077 Q020000 Y
077 Q030000 N
<PAGE>      PAGE  5
078  000000 N
080 A000000 N/A
080 C000000        0
081 A000000 N
082 A000000 N
083 A000000 N
084 A000000 N
085 A000000 Y
085 B000000 N
086 A010000      0
086 A020000      0
086 B010000     44
086 B020000    320
086 C010000      0
086 C020000      0
086 D010000      0
086 D020000      0
086 E010000      0
086 E020000      0
086 F010000      0
086 F020000      0
087 A010000 Common Stock, par value $.01 per share
087 A020000 239467103
087 A030000 DXR
088 A030000 N
088 B030000 N
088 C030000 Y
088 D030000 N
SIGNATURE   David Frankel
TITLE       CFO

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77(B)
<SEQUENCE>2
<FILENAME>ex99_77b.htm
<DESCRIPTION>EXHIBIT 99.77(B)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.77(b)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Report of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">To the Board of Directors of Daxor Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">In planning and performing our audit of the financial statements of Daxor Inc. (the Company) as of and for the year ended December 31, 2013, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Company's internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-SAR, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">The management of the Company is responsible for establishing and maintaining effective internal control over financial reporting.  In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls.  A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company's assets that could have a material effect on the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis.  A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our consideration of the Company's internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control over financial reporting that might be material weaknesses under standards established by the Public Company Accounting Oversight Board (United States).  However, we noted no deficiencies in the Company's internal control over financial reporting and its operation, including controls over safeguarding securities that we consider to be material weaknesses as defined above as of December 31, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">This report is intended solely for the information and use of management and the Board of Directors of Daxor Inc. and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">/s/ Rotenberg Meril Solomon Bertiger
&amp; Guttilla, P.C. <BR>
Saddle Brook, NJ <BR>
February 28, 2014</FONT></P>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
